SKIN CLEARANCE DATA
Proportion of patients achieving EASI 75 skin clearance
Rapid, controlled skin clearance at Week 161,2*


RINVOQ 15 mg (n=281)
RINVOQ 30 mg (n=285)
Response observed as early as 2 WEEKS2
Ranked secondary endpoint
MEASURE UP 1
38%†RINVOQ 15 mg
47%†RINVOQ 30 mg
4%Placebo
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RINVOQ 15 mg (n=276)
RINVOQ 30 mg (n=282)
Response observed as early as 2 WEEKS2
Ranked secondary endpoint
MEASURE UP 2
33%†RINVOQ 15 mg
44%†RINVOQ 30 mg
4%Placebo
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
The co-primary endpoints1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
vIGA 0/1 at Week 161,2:
8%Placebo
48%†RINVOQ 15 mg
62%†RINVOQ 30 mg
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
THE CO-PRIMARY ENDPOINTS1
were the percentage of patients achieving EASI 75 and a vIGA score of 0/1 at Week 16
vIGA 0/1 at Week 161,2:
5%Placebo
39%†RINVOQ 15 mg
52%†RINVOQ 30 mg
Response observed as early as 2 WEEKS2
Ranked secondary endpoint
MEASURE UP 1
38%†RINVOQ 15 mg
47%†RINVOQ 30 mg
4%Placebo
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
Response observed as early as 2 WEEKS2
Ranked secondary endpoint
MEASURE UP 2
33%†RINVOQ 15 mg
44%†RINVOQ 30 mg
4%Placebo
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
Durable skin clearance rates at Week 52 in a blinded extension study7,9,10*

RINVOQ 15 mg
RINVOQ 30 mg
*Monotherapy results. OC; ITT. Data are a sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.
DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; results cannot be considered statistically significant.
OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.
Proportion of patients achieving EASI 90 skin clearance
Robust EASI 90 skin clearance measured at Week 161,2*


RINVOQ 15 mg (n=281)
RINVOQ 30 mg (n=285)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RINVOQ 15 mg (n=276)
RINVOQ 30 mg (n=282)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RANKED SECONDARY ENDPOINT1
Percentage of patients achieving EASI 90 at Week 16
RANKED SECONDARY ENDPOINT1
percentage of patients achieving EASI 90 at Week 16
Durable skin clearance rates at Week 52 in a blinded extension study7,9,10*
DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; thus, results cannot be considered statistically significant.
OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.
Actual MEASURE UP patients treated with RINVOQ (15 mg) in a clinical trial. Individual results may vary.
Itch Relief Data
Proportion of patients with improvement in worst pruritus NRS ≥4
Rapid, controlled itch relief at
Week 161,2*






RINVOQ 15 mg (n=274)
RINVOQ 30 mg (n=280)
Response as early as 2 DAYS after 1st dose2
Ranked secondary endpoint
MEASURE UP 1
16%†RINVOQ 15 mg (n=275)
3%Placebo (n=270)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RINVOQ 15 mg (n=270)
RINVOQ 30 mg (n=280)
Response observed as early as 2 DAYS after 1st dose2
Ranked secondary endpoint
MEASURE UP 2
12%†RINVOQ 15 mg (n=269)
3%Placebo (n=267)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
Response as early as 2 DAYS after 1st dose2
Ranked secondary endpoint
MEASURE UP 1
16%†RINVOQ 15 mg (n=275)
3%Placebo (n=270)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
Response observed as early as 2 DAYS after 1st dose2
Ranked secondary endpoint
MEASURE UP 2
12%†RINVOQ 15 mg (n=269)
3%Placebo (n=267)
*Monotherapy results. †p≤0.001; RINVOQ vs placebo. NRI-C; ITT.
Durable rates of itch relief at Week 52 in a blinded extension study7,9,10*
RECOMMENDED DOSAGE IN AD1:
- 30 mg is not an approved starting dose
- For 12 to <65 years: Initiate with 15 mg once daily. If an adequate response is not achieved, consider increasing dosage to 30 mg once daily. Discontinue if an adequate response is not achieved with 30 mg dose. Use the lowest effective dose needed to maintain response
- For 65+ years: Recommended dosage is 15 mg once daily
DATA LIMITATIONS: Data through Week 52 were prespecified, non-ranked endpoints, not controlled for multiplicity; thus, results cannot be considered statistically significant.
OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.
Proportion of patients achieving no-to-little itch worst pruritus NRS 0/1
Rates of worst pruritus NRS 0/1 at Week 164*


RINVOQ 15 mg (n=279)‡
RINVOQ 30 mg (n=282)‡
*Monotherapy results. NRI-C; ITT.
‡n=number of patients whose baseline WP-NRS is >1.
RINVOQ 15 mg (n=275)‡
RINVOQ 30 mg (n=281)‡
*Monotherapy results. NRI-C; ITT.
‡n=number of patients whose baseline WP-NRS is >1.
DATA LIMITATIONS4: Worst pruritus NRS 0/1 was a prespecified, non-ranked additional endpoint and was not controlled for multiplicity; thus, observed differences cannot be regarded as statistically significant.
Worst pruritus NRS 0/1 captured daily through Week 16 and averaged for prior week.
DATA LIMITATIONS4: Worst pruritus NRS 0/1 was a prespecified, non-ranked additional endpoint and was not controlled for multiplicity; thus, observed differences cannot be regarded as statistically significant.
Worst pruritus NRS 0/1 captured daily through Week 16 and averaged for prior week.
*Monotherapy results. NRI-C; ITT.
‡n=number of patients whose baseline WP-NRS is >1.
Rates of worst pruritus NRS 0/1 observed at Week 52*
INTEGRATED RESULTS FROM MEASURE UP 1 AND 29,11
ALL DATA ARE OBSERVED CASES
INTEGRATED RESULTS FROM MEASURE UP 1 AND 29,11
ALL DATA ARE OBSERVED CASES

RINVOQ 15 mg
RINVOQ 30 mg
*Monotherapy results. OC. A sub-analysis of the MEASURE UP blinded extension data including only patients who were originally randomized to RINVOQ, completed the RCT, and enrolled in the blinded extension.
‡n=number of patients whose baseline WP-NRS is >1.
DATA LIMITATIONS: Worst pruritus NRS 0/1 data at Week 16 and through Week 52 were prespecified, non-ranked endpoints and not controlled for multiplicity; thus, results cannot be considered statistically significant.
OLE LIMITATIONS: There is potential for enrichment of OLE data, as those who remain in the study are aware of their treatment and generally fare better than those who discontinue. Patients may have used topical medications.
MEASURING ITCH
IMPROVEMENT1,2,5-7PATIENTS ON RINVOQ ACHIEVED AN IMPROVEMENT IN ITCH AS MEASURED BY A ≥4-POINT REDUCTION IN WP-NRS AT WEEK 16
INTEGRATED ANALYSIS OF MEASURE UP 1 AND 2

Inclusion criteria for RINVOQ phase 3 clinical trials included moderate to severe atopic dermatitis, defined by EASI ≥16, vIGA ≥3, BSA ≥10%, and WP-NRS ≥4.2
A patient with baseline score of 7 would need a score of 3 or lower to achieve improvement in WP-NRS ≥4.
ITCH RELIEF AT WEEK 16 IN A MEASURE UP PATIENT3
BASELINE

WEEK 16

Actual MEASURE UP patient treated with RINVOQ 15 mg in a clinical trial. Individual results may vary.
Are your patients seeking treatment for the rash of atopic dermatitis?
Is itch a primary concern?
Safety is important to you. Want to know more about the safety
profile of RINVOQ?
Want to know more about monitoring guidelines for RINVOQ?
RINVOQ® Complete can help patients get the support they need
to start and stay on track with their prescribed treatment.
Familiar with Complete? RINVOQ Complete offers the same
exceptional AbbVie support you know and trust.